Essential: The Pharmacy Compounding Podcast

Peptides. Animal-derived thyroid products. The perils of not documenting enough. A new recommendation for state regulation. And more.

This episode looks at some smart ways to regulate pharmacy when it comes to med spas and pop-up clinics — ways that won’t cut patients off from their meds. We also look at the latest news on the thyroid-extract front, what’s happening with peptide compounding, and a bill in California that could bode well for pharmacists nationwide.

In this episode, Andrew Kantor is joined by federal lobbyist David Pore and PCCA's Amy Shank to examine the proposed SAFE Act and its potential impact on compounding pharmacies. The discussion explores concerns that the bill could restrict patient access to compounded medications during drug shortages, impose new limitations on 503A pharmacies, and disproportionately affect legitimate compounders while failing to address bad actors. The episode also unpacks the legislation's connection to GLP-1 demand, adverse event reporting, and the bipartisan politics surrounding the bill, while encouraging listeners to stay engaged in APC's advocacy efforts.

This episode we look at some of the latest compounding news, and then we’ve got a deep dive into state-level legislation with the Leading Ladies of Pharmacy Compounding Advocacy.

This episode we look at a bunch of statements from the FDA and from HHS Secretary Robert F. Kennedy, Jr. And of course there are peptides to talk about these days. Does anyone really know what’s going on with those?

This week we look at a somewhat confusing, possibly problematic FDA statement, as well as the anti-compounding bills popping up across the country. Our Deep Dive this week is a hot topic: AI in pharmacies — how it’s being used successfully, but also how you can use it to streamline your workflow and, yes, even increase your bottom line. Our expert will tell you what to look for, and what easy pitfall you need to avoid. Links from the podcast: The troublesome FDA statement: https://fllw.me/4utzQIw APC’s Snapshot of Pharmacy Compounding: https://a4pc.org/snapshot Read more about the 2002 Supreme Court case "Thompson v. Western States Medical Center": https://www.oyez.org/cases/2001/01-344 TJM Labs: https://tjmlabs.com Join APC: https://a4pc.org/join

In this edition of Essential, we look at two major issues facing pharmacy compounding. First is a state-by-state effort by pharma companies to pass laws restricting compounding, and second is a cryptic statement from the FDA about  possible limitations on compounding with GLP-1 ingredients. They’re both Very Big Deals for pharmacists across the country.

In this edition of Essential, we’ve got concerns about the FDA’s revolving door, some issues with a new California law that might affects the whole country, and a new accreditation that might save a lot of headache. Then we take a deep dive into the once and future world of compounded peptides — where they are, and where they might be going … and why.

In this edition of Essential, we’ve got updates on some big compounding news — like the FDA’s long-overdue decision to remove the boxed warning from some menopause hormone-replacement therapy drugs. (And yes, that’s important for compounding pharmacists!)

In this edition of Essential, we look at how we’re pushing back against the FDA’s upcoming ban on desiccated thyroid extract, why drugmakers’ latest tactics against compounding pharmacies are backfiring, and we give you a great way to make sure your practice is performing at its best.